论文部分内容阅读
[目的]观察胃黏膜脱垂(GMP)的内镜下检出率及康复新液治疗GMP的临床疗效。[方法]2008年8月20日~11月18日于空军总医院行胃镜检查的1 000例患者,观察并总结GMP的胃镜下检出率。对检出的GMP患者进行临床症状及内镜下炎症评分,并按奇偶数分为2组,治疗组给予康复新液10 ml,3次/d口服;对照组给予硫糖铝混悬液10 ml,3次/d口服,随访观察3个月后复查胃镜。[结果]GMP内镜下检出率为20.4%。治疗组消化不良症状总积分降低率为(64.89±7.88)%,对照组为(40.71±10.67)%(P<0.01)。治疗组治疗后内镜下炎症积分均数从治疗前的4.037下降至1.336(P<0.01),与对照组比较差异有统计学意义(P<0.01)。[结论]GMP内镜下检出率较高;康复新液对GMP消化不良症状和内镜表现的改善优于硫糖铝混悬液。
[Objective] To observe the endoscopic detection rate of gastric mucosal prolapse (GMP) and the clinical effect of Kangfuxinye on GMP. [Method] From August 20, 2008 to November 18, 2008, 1 000 patients underwent gastroscopy in Air Force General Hospital were observed and summarized. The clinical symptoms and endoscopic inflammatory score of GMP patients were detected and divided into two groups according to even and odd numbers. The treatment group was given Kangfuxin solution 10 ml orally 3 times a day. The control group was given sucralfate suspension 10 ml, 3 times / d orally, follow-up observation of gastroscopy after 3 months. [Results] The detection rate of GMP was 20.4%. The total score of dyspeptic symptoms was (64.89 ± 7.88)% in the treatment group and (40.71 ± 10.67)% in the control group (P <0.01). After treatment, the average score of inflammatory endoscopy in the treatment group decreased from 4.037 to 1.336 before treatment (P <0.01), and the difference was statistically significant (P <0.01) compared with the control group. [Conclusion] The detection rate of GMP in endoscopy is high. The improvement of dyspeptic symptom and endoscopic performance of GMP is better than that of sucralfate suspension.